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ABSTRACT
Purpose: The objective of this study was to compare the estimated cost of clinical and surgical treatment for basl cell
carcinoma of the eyelid. Methods: This was a pilot study of 12 patients with basal cell carcinoma receiving treatment
with 5% imiquimod cream at the ocular plastic surgery center, medical school University of São Paulo (HC-FMUSP,
Brazil). The cost of clinical treatment was estimated based on the time of treatment and amount of medication
consumed by patients in the home setting. The cost of surgical treatment was estimated by ophthalmologists with
experience in reconstructive plastic surgery based on analysis of images of the same patients. Surgeons responded to
a questionnaire with four questions about surgical technique, surgical materials required, estimated duration of
surgery and type of anesthesia.Results: Immunotherapy lasted from 8 to 12 weeks. All patients reported each cold-
stored sachet with 5% imiquimod cream lasted 3 days. According to the institution, a box with 12 sachets costs BRL
480.00. Patients required 1.58-3.11 boxes for complete treatment, corresponding to a total cost of BRL 758.40-
1,492.80. Based on image analysis, surgeons evaluated surgery would require 1-3 hours. The estimated cost of
surgery room and staff was BRL 263.00, to which the cost of supplies was added. Thus, the total cost of surgical
treatment was BRL 272.61-864.82. On the average, immunotherapy was 57,64% more costly than surgical treatment.
Conclusions: Malignant eyelid tumors are a common finding in clinical ophthalmology. Surgery is still the treatment
of choice at our institution, but immunotherapy with 5% imiquimod cream may be indicated for patients with
multiple lesions or high surgical risk and for patients declining surgery for reasons of fear or esthetic concerns. The
ability to estimate costs related to the treatment of malignant eyelid tumors is an important aid in the financial
planning of health care institutions. Further studies should evaluate the possibility of institutions equating the cost of
immunotherapy and surgical treatment by acquiring similar but less expensive medications.
Keywords: Carcinoma, basal cell carcinoma/surgery; Carcinoma, basal cell  /economy; Carcinoma, basal cell
carcinoma/drug therapy; Eyelid neoplasms; Antineoplastic agents/therapeutic use; Biopsy; Health care costs
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INTRODUCTION
Basal cell carcinoma (BCC) is the most commontype of periocular neoplasm, with an annualincidence of 10%.(1) In the periocular area, BCC
currently represents 20% of all tumors and 90% of
neoplasms.2 The increasing incidence makes it urgent to
evaluate treatment costs and financial impacts on public
health system.
Considered reliable and effective, surgical
excision with safety margins, followed by primary
reconstruction of the affected area, is the standard
treatment for periocular BCC.(3) However, the periocular
region is difficult to manage, requiring special surgical
techniques to avoid damage to eyelid function. In
addition, surgical treatment often involves the removal
of a large amount of tissue in detriment of the patient’s
appearance.(4) Several alternative therapies have been
proposed to help patients with contraindication for
conventional treatment. One of these, immunotherapy
with 5% imiquimod cream, has been widely tested and
found to be efficacious in the treatment of BCC.(5-7)It is
supposed to be costly, but an economic evaluation, with a
cost-outcome analysis, is necessary to estimate the actual
contribution of this procedure in skin cancer treatment,
in comparison with the reference procedure, ie traditional
surgical excIt is supposed to be costly, but an economic
evaluation, with a cost-outcome analysis, is necessary to
estimate the actual contribution of this procedure in skin
cancer treatment, in comparison with the reference
procedure, ie traditional surgical excision.
Few studies have compared the cost-effectiveness
of surgical and clinical treatment for superficial BCC.
Exceptions include a study on patients with BCC in the
lower limbs8 and a study comparing dermatological and
non-dermatological services.(9) However, no previous
study compared the cost of clinical and surgical treatment
of BCC in the periocular area.
METHODS
This pilot study, conducted at the Ocular Plastic
Surgery Center (HC-FMUSP, Brazil), involved 12 patients
with periocular lesions meeting the inclusion criteria for
treatment with 5% imiquimod cream. All lesions were
nodular BCC confirmed by 2-mm punch biopsy.
RESUMO
Objetivo: O objetivo deste estudo foi comparar os custos do tratamento clínico e cirúrgico para carcinoma basocelular
palpebral. Método: Neste estudo piloto, doze pacientes com carcinoma basocelular atendidos no departamento de
Plástica Ocular do Hospital das Clínicas da Universidade de São Paulo (HC-FMUSP) foram tratados com
imiquimode creme 5%. O Custo do tratamento clínico foi estimado baseado no tempo de tratamento e quantidade
de medicação utilizada pelo paciente no domicilio. O custo do tratamento cirúrgico foi baseado na análise das
imagens dos mesmos pacientes submetidos ao tratamento clínico, por Oftalmologistas experientes em cirurgia
plástica reconstrutiva. Os profissionais responderam um questionário com quatro perguntas relacionadas à técnica
cirúrgica, à quantidade de material gasto, ao tempo cirúrgico estimado e anestesia utilizada. Resultados: O tempo de
tratamento clínico variou entre 8 a 12 semanas. Todos os pacientes referem que um sachê dura 3 dias e armazena-
ram na geladeira. O valor informado pela instituição na compra do imiquimode creme 5% foi de 40,00 reais/sachê,
portanto o custo da caixa medicação foi de R$ 480,00 a caixa. A média de caixas consumidas por tratamento variou
de 1,58 a 3,11 caixas, portanto o custo do tratamento clínico variou de R$ 758,40 a R$1.492,80. Os cirurgiões
avaliaram as imagens dos pacientes submetidos ao tratamento clínico e informaram que o tempo estimado de
cirurgia para cada paciente seria de 1 a 3 horas se a opção fosse cirúrgica. Foi estimado um custo de centro cirúrgico,
incluindo espaço físico e pessoal de R$ 263,00 ao qual foi acrescido o valor do material que seria utilizado. Assim,
observou-se que o valor variou entre R$ 272,61 a R$ 864,82 para o tratamento cirúrgico.  O tratamento clínico em
média foi de 57,64% superior ao tratamento cirúrgico. Conclusão:  As lesões palpebrais malignas são responsáveis
por uma porção importante na prática clínica oftalmológica. A cirurgia continua sendo o padrão ouro em nossa
instituição, porém casos em que a cirurgia não é uma opção, como pacientes com alto risco cirúrgico, aqueles com
múltiplas lesões ou que se negam a cirurgia, seja por fobia ou motivo estético, podemos lançar mão de terapias
alternativas como a imunoterapia com o imiquimode creme 5%. Conhecer a estimativa dos custos relacionados ao
tratamento dessa patologia é fundamental para o planejamento financeiro das instituições. A instituição com a
possibilidade de aquisição de uma mesma medicação com valor mais acessível permitiria equilibrar o custo do
tratamento clínico com o cirúrgico e deverão ser avaliados em trabalhos futuros
Descritores: Carcinoma basocelular/cirurgia; Carcinoma basocelular/economia Carcinoma basocelular/
quimioterapia; Neoplasias palpebrais; Antineoplásicos/uso terapêutico; Biópsia; Custos de cuidados de saúde
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Inclusion criteria
- Periocular basal cell carcinoma confirmed by
biopsy;
- Clinical contraindication for surgical
intervention;
- Refusal to submit to surgery for aesthetic or
psychological reasons;
- Signing of informed consent form.
Exclusion criteria
- Previous treatment (in case of recurrence);
- Age under 12 years;
- Pregnancy or breastfeeding;
- Autoimmune disorder or previous inflammatory
disease;
- Immunodepression.
The cost of clinical treatment was estimated
based on the time of treatment and amount of
medication used by patients in the home setting. The
cost of surgical treatment was estimated by
ophthalmologists with experience in reconstructive
plastic surgery based on analysis of images of the same
patients. Surgeons were given a questionnaire with
four questions about surgical technique, surgical
materials required, estimated duration of surgery and
type of anesthesia.
RESULTS
Immunotherapy lasted from 8 to 16 weeks8.
Patients reported that each cold-stored sachet with 5%
imiquimod cream lasted 3 days. According to the
institution, in 2008/2009 the cost of one sachet was BRL
40.00 (BRL 480.00 for a box with 12 sachets).
Patients required 1.58–3.11 boxes for complete
treatment, corresponding to a total cost of BRL 758.40–
1,492.80 (Table 1).
Based on image analysis, surgeons estimated
surgery would require 1–3 hours. Based on earlier studies
from the same institution, 9,10 the cost of surgery room
and staff was estimated to be BRL 263.00, to which the
cost of supplies was added (Table 2).
Thus, the total cost of surgical treatment was BRL
272.61–864.82. On the average, immunotherapy was
57.64% more costly than surgical treatment.
Breakdown Month Day Hour Minute
Human resources 34,337.25 2,376.86 237.69 3.96
Facilities 4,885.00 244.25 24.43 0.41
Depreciation of equipment 200.00 16.67 1.67 0.03
Total 39,422.25 2,637.78 263.79 4.40
Table 2
Estimated cost in BRL of surgery room and staff at the
Ocular Plastic Surgery Center (HC-FMUSP)
Patient Size of Boxes (12 sachets) Cost of clinical Estimated cost
lesion(mm) of 5% imiquimod treatment in BRL* of surgical
cream consumed treatment in BRL
1 11 x 8 1.58    758.40 594.54
2 11 x 10 2.33 1,118.40 864.80
3 11 x 9 2.33 1,118.40 601.04
4 19 x 11 2.52  1,209.60 601.04
5 12.5 x 5 3.11  1,492.80 502.77
6 27 x 10 2.33  1,118.40 543.81
7 5 x 5 1.58     758.40 272.61
8 5 x 5 2.72  1,305.60 272.61
Table 1
Cost of clinical treatment versus estimated cost of surgical
treatment for periocular basal cell carcinoma
(*)According to the institution, in 2008/2009 the cost of a box with 12 sachets of 5% imiquimod
cream was BRL 480.00
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DISCUSSION
Malignant eyelid tumors constitute an important
part of clinical ophthalmology. At our institution, surgery
is still the treatment of choice, except in patients with
high surgical risk, multiple lesions or refusal to submit to
surgery for aesthetic or psychological reasons. Such
patients may opt for immunotherapy with 5% imiquimod
cream. Knowledge of treatment costs is an essential
subsidy to the financial planning of health care
institutions.
Aguilar et al.   evaluated the cost of treatment for
superficial BCC in the lower limbs. Surgery was found to
be more costly, but also more efficacious, than clinical
treatment.(11)
Vanaclocha et al.   evaluated the cost-effectiveness
of treatment of superficial BCC using surgical excision or
5% imiquimod cream at dermatological and non-
dermatological services and found that clinical treatment
reduced patient cost compared to surgery.(12) In addition,
the cost was higher at non-dermatological services due to
more expensive surgical procedures and postoperative care.
Surgical treatment was less costly in our study than
in the literature. However, the duration of surgery and
need of supplies may have been underestimated by the
fact that estimates were based on image analysis.
Nevertheless, we believe that even if corrected for this
difference, surgery would still be significantly less
expensive than immunotherapy, especially in view of
the low fixed labor costs of Brazilian public institutions.
The cost of clinical treatment was similar to what
has been reported from other countries, but prolonged
treatment would be financially unfeasible in the context
of Brazilian public health care. The possibility of reducing
clinical cost to the level of surgical cost through bulk
purchase of less expensive but equivalent brands of
medication might be explored in future studies.
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